Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 18,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Phase 1 Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study In Healthy Elderly People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses Of PF-06743649

NCT02170012
View directory record Official record
Conditions
Healthy Elderly
Interventions
PF-06743649, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
65 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases

NCT00026494
View directory record Official record
Conditions
Metastatic Cancer
Interventions
temozolomide, vinorelbine tartrate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 18, 2016 · Synced Oct 30, 2026, 10:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

NCT05438329
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
DB-1305/BNT325, Pembrolizumab, BNT327
Drug · Combination Product
Lead sponsor
DualityBio Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
42
States / cities
Bullhead City, Arizona • Cerritos, California • La Jolla, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate Cancer

NCT00348595
View directory record Official record
Conditions
Prostate Cancer
Interventions
Revlimid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 12, 2019 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)

NCT02914639
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
SF0166 Topical Ophthalmic Solution
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

NCT04495257
View directory record Official record
Conditions
Advanced Melanoma, Renal Cell Carcinoma
Interventions
Nivolumab, Ipilimumab, APX005M
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Terminated Phase 1 Interventional Results available

Safety of Bryostatin in Patients With MS

NCT06190912
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Bryostatin 1
Drug
Lead sponsor
Robert Fox
Other
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Recruiting Phase 1 Interventional

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 2001
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Terminated Phase 1 Interventional Results available

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

NCT03110354
View directory record Official record
Conditions
Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute
Interventions
DS-3201b
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
6
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 30, 2026, 10:32 AM EDT
Recruiting Phase 1 Interventional

Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease

NCT07566494
View directory record Official record
Conditions
Sickle Cell Disease, Hemolytic Anemia
Interventions
VAS-101
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Terminated Phase 1 Interventional

Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer

NCT04421222
View directory record Official record
Conditions
Prostate Cancer
Interventions
EPI-7386 (QD), EPI-7386 (BID), Abiraterone acetate, Apalutamide
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
7
States / cities
Port Saint Lucie, Florida • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2025 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

NCT02987829
View directory record Official record
Conditions
Metastatic Castrate-resistant Prostate Cancer, Adenocarcinoma, Prostate
Interventions
TRC253
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 99 Years · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Santa Monica, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 30, 2026, 10:32 AM EDT
Terminated Phase 1 Interventional

A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies

NCT03333031
View directory record Official record
Conditions
Solid Tumor
Interventions
HS-196
Drug
Lead sponsor
Herbert Lyerly
Other
Eligibility
18 Years to 99 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1Phase 2 Interventional

Stem Cell Transplant for Patients With Blood Malignancy Using Donors and Less Toxic Chemotherapy With CAMPATH 1H

NCT00048412
View directory record Official record
Conditions
Myelodysplastic Disorders, Leukemia, Multiple Myeloma, Plasma Cell Dyscrasia, Lymphoproliferative Disorders
Interventions
FLUDARABINE, CAMPATH 1H, FK50, Stem Cell Collection and Infusion
Drug · Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 30, 2026, 10:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

NCT00022230
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, sargramostim, therapeutic autologous lymphocytes, cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Biological · Drug
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 30, 2026, 10:32 AM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

NCT06358430
View directory record Official record
Conditions
Colorectal Cancer, Minimal Residual Disease
Interventions
Fludarabine Phosphate, Cyclophosphamide, Cetuximab, TROP2-CAR-NK Cells, Rimiducid (AP1903), Lymphodepleting Chemotherapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients

NCT00002128
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimate The Effect Of Repeat-Dose Rifampin On The Pharmacokinetics Of CP-690,550 In Healthy Volunteers

NCT01204112
View directory record Official record
Conditions
Healthy
Interventions
Tasocitinib (CP-690,550) plus Rifampin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 22, 2010 · Synced Oct 30, 2026, 10:32 AM EDT
Recruiting Phase 1 Interventional

A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)

NCT05885412
View directory record Official record
Conditions
PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Interventions
RP-A601
Genetic
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
La Jolla, California • Durham, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00104767
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 30, 2026, 10:32 AM EDT
Terminated Phase 1 Interventional

BAY1238097, First in Man

NCT02369029
View directory record Official record
Conditions
Neoplasms
Interventions
BAY 1238097
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2016 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

NCT04485702
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Midazolam injection, Ketamine Injectable Product, MELT-100
Drug
Lead sponsor
Melt Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2021 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional Results available

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
Interventions
MDX-1106
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 30, 2026, 10:32 AM EDT
Completed Phase 1 Interventional

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

NCT01598077
View directory record Official record
Conditions
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma
Interventions
LJM716
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 30, 2026, 10:32 AM EDT